Daewoong launches BTX in Australia, completing expansion across 5 continents

Daewoong Pharmaceutical said Monday that its botulinum toxin (BTX), Nabota, branded as Nuceiva in Australia, has officially launched in the Australian market through its global partner, Evolus. 

The BTX product is branded as Jeuveau in the U.S. and Canada, Nuceiva in the E.U. and the U.K., and Clodew in Argentina.

The Australian launch signifies the completion of Nuceiva’s rollout across five continents. Since receiving U.S. FDA approval in 2019, the BTX has made its mark in North America, South America, Europe, Asia, and now Oceania. The Therapeutic Goods Administration (TGA) in Australia approved Nuceiva prabotulinumtoxinA 100 Units powder for solution for injection vial in January 2023.

Nuceiva is noted for its high purity, a feature Daewoong attributes to its patented Hi-Pure Technology. The product has been approved in 68 countries, with partnerships established in over 80 nations, and has captured a 12 percent market share in the U.S..

Evolus introduced Nuceiva to Australian medical professionals at Aesthetics 2024, a medical aesthetics event held in Sydney from Aug. 1 to 4, which drew more than 200 participants. Following this launch, Evolus plans to boost Nuceiva's presence through local educational initiatives and seminars in Australia.

“There is a growing interest among younger Australians in non-surgical aesthetic procedures,” said Dr. Steven Liew, an Australian plastic surgeon at Shape Clinic in Sydney who attended the launch. “I anticipate that Nuceiva will provide a valuable new option for Australian practitioners.”